Renal Denervation

This channel includes news and new technology innovations for renal denervation used to treat hypertension. Renal denervation is a catheter-based therapy. The catheter is into the renal artery and delivers radio-frequency energy to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys. This enables greater filtration of the blood and removal of excess water that causes hypertension

Medtronic Presents Positive Renal Denervation Results at EuroPCR 2019
News | Renal Denervation | May 23, 2019

May 23, 2019 – Investigators unveiled late-breaking clinical data from a first-of-its-kind physician sponsored...

 Pulmonary artery denervation for CpcPH from the PADN-5 trial. #TCT2017

A series of procedural images of a pulmonary artery denervation for CpcPH from the PADN-5 trial.

News | Hypertension | October 04, 2018

October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and...

Paradise Renal Denervation System Shows Significant Blood Pressure Reduction in Hypertensive Patients. PCR, #euroPCR 2018
News | Renal Denervation | May 30, 2018

May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO...

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

An example of renal denervation therapy being delivered. A catheter is inserted into the renal artery to ablate the nerves in the vessel wall that regulate vasoconstriction. This leaves the vessel permanently in the widest open position to allow greater blood flow to the kidneys.

Feature | Renal Denervation | May 30, 2018

May 30, 2018 — Despite the best efforts of clinicians to manage hypertension, it continues to increase and is now...

Renal Denervation Shows Significant Drop in Hypertension
News | Renal Denervation | May 23, 2018

May 23, 2018 – At the 2018 EuroPCR Annual Meeting in Paris, Medtronic announced first-ever-data from the SPYRAL HTN-...

Medtronic Announces Renal Denervation Pivotal Trial for Hypertension Treatment
News | Renal Denervation | April 16, 2018

April 16, 2018 — Medtronic plc announced U.S. Food and Drug Administration (FDA) approval to begin an...

SPYRAL HTN-OFF MED Study Results Show Efficacy, Safety of Renal Denervation
News | Renal Denervation | August 31, 2017

August 31, 2017 — Medtronic plc announced its intent to move forward with a new...

News | Renal Denervation | October 11, 2016

October 11, 2016 — Awards from the National Institutes of Health’s Common Fund are supporting research on the...

Technavio report, renal denervation devices, 2015
News | Renal Denervation | August 23, 2016

August 23, 2016 — Technavio analysts forecast the global...

renal denervation, resistant hypertension, rat study, American Journal of Physiology
News | Renal Denervation | February 17, 2016

February 17, 2016 — Up to 10 percent of people with high blood pressure have...

Medtronic, SYMPLICITY AF, PVI, renal denervation, Arctic Front, Spyral, G3
Feature | May 05, 2015

May 5, 2015 — Medtronic plc announced the start of a clinical...

Vessix Renal Denervation System, REDUCE-HTN: REINFORCE, high blood pressure

Vessix System image courtesy of Boston Scientific Corp.

News | May 04, 2015

May 4, 2015 — Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix...

Feature | April 01, 2015

April 1, 2015 — Medtronic plc announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a phased...

Overlay Init